Company Overview
About Cellanome
Cellanome is a biotechnology tools company founded in 2021 and headquartered in Menlo Park, California. The company is developing a next-generation multi-omics platform designed to simultaneously measure multiple layers of biological information — including genomics, transcriptomics, and proteomics — at single-cell resolution and at unprecedented scale. Its platform integrates genome sequencing, microfluidics, and proprietary integrated sensors to capture a more complete molecular portrait of individual cells than any existing single-omics technology can achieve alone.
Business Model & Competitive Advantage
Cellanome raised a $100M Series A in 2023 co-led by GV (Google Ventures) and Andreessen Horowitz (a16z Bio), with participation from Meritech Capital and others — a rare nine-figure Series A that signals exceptional investor conviction in the platform's potential. The company's technology is aimed at transforming how researchers understand complex biological systems, with applications in drug discovery (identifying new drug targets by characterizing disease cell populations), diagnostics (detecting disease-associated cellular changes at high resolution), and fundamental cell biology research.
Competitive Landscape 2025–2026
The single-cell multi-omics tools market is growing rapidly, driven by demand from pharmaceutical companies, academic research institutions, and biotech drug developers. Cellanome competes with established genomics tools companies — principally 10x Genomics (which dominates single-cell transcriptomics) — as well as emerging multi-omics platforms from companies like Parse Biosciences and Scale Bio. Cellanome's differentiation lies in the integration of multiple measurement modalities (not just gene expression but also protein and epigenetic layers) within a single cell, at scale, which has been the frontier challenge in the field.
Key Differentiators
Emerging Innovator
Cellanome is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Cellanome with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Cellanome? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Cellanome Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Cellanome vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →